Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Analysts Review
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, May 16, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Thermo Fisher Scientific Inc. (NYSE: TMO), Agilent Technologies Inc. (NYSE: A), United Therapeutics Corporation (NASDAQ: UTHR), Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) and Centene Corporation (NYSE: CNC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2368-100free.
Thermo Fisher Scientific Inc. Analyst Notes
On May 5, 2014, Thermo Fisher Scientific Inc. (Thermo Fisher Scientific) announced that it will conduct its 2014 Analyst Meeting, on Tuesday, May 20, 2014, from 9:00 a.m. to noon, EDT, at the New York Hilton Midtown, 1335 Avenue of Americas, New York City. The Company informed that the Analyst Meeting will feature presentations from members of the Company's Senior Management team which will also include future financial performance outlook. Thermo Fisher Scientific added that the webcast can be accessed through the Company's website. The full analyst notes on Thermo Fisher Scientific are available to download free of charge at:
Agilent Technologies Inc. Analyst Notes
On May 8, 2014, Agilent Technologies Inc. (Agilent) presented an enhanced version of OpenLAB CDS: Peak Explorer for single-click peak integration and intelligent reporting. According to the Company, the newly added features boost throughput for petrochemical, chemical, and other industry laboratories that processes large numbers of complex samples. "Agilent continues to expand OpenLAB CDS to deliver time and cost savings to help labs achieve greater productivity," remarked Thomas Schmidt, OpenLAB CDS Product Manager, Agilent. "The new release of OpenLAB CDS dramatically reduces the time needed to review complex data, manually re-integrate peaks and view report results." The Company stated that OpenLAB CDS is one of the leading OpenLAB Suite of software products built to capture, analyze, and share scientific information. Its intelligent reporting features automatic drag-and-drop chromatography reporting which makes it easy to build reports without transferring data to other software. The full analyst notes on Agilent are available to download free of charge at:
United Therapeutics Corporation Analyst Notes
On May 6, 2014, Lung Biotechnology Inc., a subsidiary of United Therapeutics Corporation's (United Therapeutics) announced that it has signed a multi-year collaborative research and development agreement with Synthetic Genomics Inc. (SGI). According to the Company, the collaboration aims to develop humanized pig organs using synthetic genomic advances which will focus on developing organs for human patients in need of transplantation, primarily on lung diseases. "Our new collaboration with Synthetic Genomics is huge for accelerating our efforts to cure end-stage lung disease. Our combined expertise should enable us to develop an unlimited supply of transplantable organs, potentially helping millions of patients who die from end-stage organ disease," said Martine Rothblatt, Ph.D., United Therapeutics Chairman and CEO. The full analyst notes on United Therapeutics are available to download free of charge at:
Keryx Biopharmaceuticals, Inc. Analyst Notes
On May 6, 2014, Keryx Biopharmaceuticals, Inc. (Keryx) announced the opening of its Boston, Massachusetts office where a significant portion of the operations is being planned to support the commercial, regulatory, medical affairs, legal, public affairs, and pharmacovigilance aspects for the possible launch of Zerenex in the US. "Boston is a biopharmaceutical hub with an exceptional pool of talent with relevant experience, which we believe makes it an ideal place to build a top-notch commercial stage organization," said Greg Madison, Chief Operating Officer of Keryx. The full analyst notes on Keryx are available to download free of charge at:
Centene Corporation Analyst Notes
On May 6, 2014, Centene Corporation (Centene) reported that it has received the recognition for five of its innovative member programs from Dorland Health's Fifth Annual Case in Point Platinum Awards on May 5, 2014. According to the Company, the award-giving program recognizes case management programs that deliver constant efficiency and effectiveness across various disciplines in care coordination. Centene and its subsidiaries: Cenpatico of Arizona, NurseWise, Peach State Health Plan, and Sunshine Health won awards in five categories: Disease Management/Population Health (Managed Care), Long-Term Care, Managed Care, Pediatric Case Management, and Wellness/Prevention. "Our clinical programs are critical to helping Centene and its subsidiaries provide access to quality, integrated healthcare for our members. We are honored to be recognized by Dorland Health with these prestigious awards for the fifth year in a row," said Mary Mason, M.D., Senior Vice President and Chief Medical Officer, Centene. The full analyst notes on Centene are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.